Rathke's cleft cysts are known to cause hormone-related abnormalities. However, the natural history of this disorder is obscure, so it is rarely associated with acute adrenal insufficiency. We herein describe a case of Rathke's cleft cyst associated with acute adrenal insufficiency in a 27-year-old man. The patient experienced severe headaches due to acute adrenal insufficiency without changes in the size of the cyst. Glucocorticoid administration improved these symptoms, and the cyst spontaneously shrank before operation. This case led us to conclude that Rathke's cleft cysts should be considered in the differential diagnosis of patients who present with adrenal insufficiency, and that the cysts can be reduced by glucocorticoids.
Introduction
Anterior pituitary hormone deficit is commonly associated with Rathke's cleft cyst (19-81% of cases) (1) , and adrenal insufficiency is reportedly found in 8% of all cases (2); on the other hand, acute adrenal insufficiency is rare (3) and the literature contains no case reports of acute adrenal insufficiency proven by a last-minute blood test showing normal sodium levels. Moreover, glucocorticoid replacement has been reported to shrink Rathke's cleft cysts (4, 5) . This case report describes a rare case of Rathke's cleft cyst that was associated with acute adrenal insufficiency, ruptured before operation, and shrank after glucocorticoid administration.
Case Report
A 27-year-old man complained of left hemianopia and a pulsing headache. Magnetic resonance imaging (MRI) performed at another clinic had revealed an intra-and suprasellar cystic lesion. He visited our hospital because of this cystic lesion and worsening symptoms. The symptoms had gradually appeared four weeks prior to his visit. At presentation, his consciousness was clear, and physical assessment revealed normal vital signs and no visual field loss. There were no signs of hemianopia. The results of the neurological examination were normal. His medical, social, and family histories were unremarkable. His laboratory test results were all within the normal range: WBC 5,500/μL, Hb 14.0 g/dL, platelets 18.3×10 4 /μL, sodium 142 mEq/L, potassium 3.8 mEq/L, chloride 105 mEq/L, blood urea nitrogen 10 mg/dL, creatinine 0.8 mg/dL, aspartate aminotransferase 17 IU/L, and alanine aminotransferase 25 IU/L.
His hormone levels were as follows: adrenocorticotropic hormone 62.0 pg/mL, cortisol 18.3 μg/dL, prolactin 15.8 ng/ mL, growth hormone 2.62 ng/mL, luteinizing hormone 3.2 mIU/mL, follicle-stimulating hormone 4.7 mIU/mL, thyroidstimulating hormone 1.77 μIU/mL, free triiodothyronine 3.41 pg/mL, and free thyroxine 1.31 ng/dL. MRI showed a sharply marginated intra-and suprasellar cystic lesion, 26×20 mm in diameter, which extended up to the optic chiasm. The lesion appeared hyperintense on T2-weighted MR images and hypointense on T1-weighted images, whereas no contrast enhancement was observed inside the lesion and only slight contrast enhancement was observed in the margin of the cyst. The intensity of the signal inside the lesion differed from that of the spinal flow (Fig. 1) . Computed tomography did not show calcification. We diagnosed Rathke's cleft cyst based on these findings.
The patient was admitted to our hospital for a worsening headache 7 days after his initial visit. Computed tomography indicated no pituitary apoplexy. Acute dizziness, nausea, limb weakness, and consciousness disturbance had appeared. A blood examination showed hyponatremia (sodium: 112 mEq/L). We suspected adrenal insufficiency and administered hydrocortisone (200 mg/day). Apart from a slight headache, all symptoms and the hyponatremia improved after the treatment. Endocrinological examination to determine the cause of the hyponatremia showed central adrenal insufficiency (adrenocorticotropic hormone: 6.1 pg/mL, cortisol: 1.0 μg/dL). Masked diabetes insipidus appeared as a result of the hydrocortisone treatment, but was treated by desmopressin. We initially planned an operation, which is the standard procedure for symptomatic Rathke's cleft cyst. However, an MRI on day 26 showed a reduction in the cyst size. Conservative therapy improved his symptoms, and the hydrocortisone and desmopressin doses were consequently tapered. Lastly, we terminated the hydrocortisone and desmopressin treatments on days 102 and 167, respectively. Fig. 2 shows the chronological changes in the sodium levels and urine osmolarity, and of the Rathke's cleft cyst. An endocrinological provocation test on day 21 showed that the patient's thyroid-stimulating hormone, growth hormone, luteinizing hormone, follicle-stimulating hormone, and prolactin responses were impaired (Table A) . However, on day 123, his thyroid-stimulating hormone response had improved while his cortisol response was impaired (Table B) . Subsequent endocrinological provocation tests on days 277 and 485 showed the same results (data not shown).
Discussion
We herein report a rare case of Rathke's cleft cyst associated with visual disturbance. In this case, the cyst caused acute adrenal insufficiency without changing in size, though it shrank following glucocorticoid administration. Previous reports have noted that Rathke's cleft cysts can cause acute adrenal insufficiency, though such an occurrence is very rare (3) . In the present case, a blood test on day 2 revealed normal sodium levels and indicated that there was no adrenal insufficiency. Nevertheless, acute adrenal insufficiency developed shortly thereafter.
The size of our patient's cyst did not change between days 4 and 9, indicating that Rathke's cleft cysts can cause symptoms without changing in size. Two potential causes of the acute adrenal insufficiency exist in this case. First, the lower intensity of the cyst on the T1-weighted image on day 9 indicated recovery from a hemorrhage. Therefore, inflammation secondary to a slight hemorrhage of the Rathke's cleft cyst around day 4 might have caused acute adrenal insufficiency. Alternatively, abacterial meningitis secondary to slight emigration from the cyst might have occurred at around the same time, resulting in acute adrenal insufficiency.
Moreover, this case leads us to believe that glucocorticoid replacement therapy may be a rational therapeutic strategy for symptomatic Rathke's cleft cysts. A Japanese study found that 15.9% of Rathke's cleft cysts spontaneously decreased in size with glucocorticoid replacement (6) . It has been reported to result in a size reduction of Rathke's cleft cysts in other published studies as well (4, 5) . In this case, there were two potential reasons for the cyst's change in size from day 9 to day 26. First, a spontaneous rupture may have induced rapid size changes. However, this would likely cause heavy headaches, and our patient's headaches did not worsen between days 9 and 26. The second idea is a size reduction induced by the strong glucocorticoid replacement therapy, which we consider more likely. For this reason, we regard glucocorticoid replacement therapy as a rational therapeutic strategy for Rathke's cleft cysts owing to its replacement of steroids, anti-inflammatory effects, and the fact that it has been previously demonstrated to achieve size reduction.
The relapse rate and risk factors for relapse of spontaneous involution of Rathke's cleft cyst are currently unknown, but likely include inflammation. Most relapses reportedly 
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occur within 5-6 years after surgery, thus suggesting that patients need to be followed up for at least 5 years (1). Accordingly, we plan to follow the present patient for at least 5 years with regular inflammatory marker examinations and imaging studies. We witnessed a case of Rathke's cleft cyst associated with acute adrenal insufficiency without size changes of the cyst, which shrunk after glucocorticoid replacement therapy. Accordingly, Rathke's cleft cyst should be considered in the differential diagnosis of acute adrenal insufficiency even in the absence of size changes. Furthermore, we believe that glucocorticoid replacement is a rational therapeutic strategy for this disorder.
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